capecitabine + cyclophosphamide + aspirin

This is an **oral combination regimen** containing **capecitabine**, **cyclophosphamide**, and **aspirin**, used primarily in the treatment of metastatic breast cancer and investigated in metastatic colorectal cancer, especially in patients progressing after prior standard chemotherapy. - **Capecitabine** is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis and inducing apoptosis in dividing cancer cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death. It also upregulates thymidine phosphorylase (TP), the enzyme that converts capecitabine to active 5-FU within tumors, resulting in potential synergy. - **Aspirin** is a non-steroidal anti-inflammatory drug (NSAID), irreversibly inhibiting cyclooxygenase (COX)-1 and COX-2. It may provide adjunctive benefits via anti-inflammatory, antiplatelet effects, and potential modulation of tumor microenvironment. This combination is typically administered orally, with various fixed-dose combinations of capecitabine and cyclophosphamide developed to improve compliance and efficacy, notably in India for metastatic breast cancer[3][4][9]. Clinical trials have also explored the addition of low-dose aspirin to capecitabine and cyclophosphamide for metastatic colorectal cancer, seeking improved outcomes with multimodal therapy[1][2][5].

Brand names

capecitabine + cyclophosphamide + aspirin

Other names

capecitabine + cyclophosphamide + aspirin